Cl-NQTrp could be a unique potential therapeutic for AD since it targets aggregation of both Aβ and tau.
Cl-NQTrp significantly alleviates the shorter life span of htau-expressing flies, leading to 58% viability on day 29.
Animal Model: |
Virgin females, carrying either the eye GMR -Gal4 driver or the pan-neuronal driver elav -Gal4 on chromosome X, were collected and crossed with males carrying UAS-h tau on the 2nd chromosome or with wild-type Oregon-R (OR) males as a control.
|
Dosage: |
0.75 mg/mL. |
Administration: |
Dripped every other day. |
Result: |
Inhibited PHF6 aggregation and ameliorates eye neurodegeneration Drosophila overexpressing the human tau protein (htau). |